Sphingolipids in Major Depression

• Main Authors: Peter L. Jernigan, Richard S. Hoehn, Heike Grassmé, Michael J. Edwards, Christian P Müller, Johannes Kornhuber, Erich Gulbins
• Format: Article
• Language: English
• Published: Cell Physiol Biochem Press GmbH & Co KG 2015-12-01
• Series: Neurosignals
• Subjects: Acid sphingomyelinase; Major depression; Neurogenesis; Ceramide
• Online Access: http://www.karger.com/Article/FullText/442603

Major depression is one of the most common and severe diseases affecting the world's population. However, the pathogenesis of the disease remains inadequately defined. Previously, a lack of monoaminergic neurotransmitters was the focus of pathophysiological concepts; however, recent concepts focus on a alteration of neurogenesis in the hippocampus. This concept suggests that neurogenesis is decreased in major depression with a rarefication of neuronal networks and a lack of new, immature neurons in the hippocampus, events that may result in the clinical symptoms of major depression. However, molecular targets involved in the pathogenesis of major depression and, in particular, a reduction of neurogenesis, are largely unknown. We have recently discovered that an inhibition of the acid sphingomyelinase/ceramide system mediates the effects of tri- and tetracyclic antidepressants. Moreover, an accumulation of ceramide in the hippocampus results in depression-like symptoms. This suggests the acid sphingomyelinase/ceramide system is very important in the pathogenesis of major depression.